Axon Enterprise vs. Celsius: Comparing Steady Incremental Gains and Historical Volatility in Quarterly Revenue Trends

Axon Enterprise has delivered 30%+ year-over-year revenue growth in every quarter over the last eight quarters, with revenue rising 66% from Q3 2024 to Q2 2026 (vs. Celsius up 204% over the same span but with decelerating momentum). For the quarter ended June 30, 2026, Axon reported an ~5% operating margin compared with Celsius at ~9% amid leadership changes and legal investigations tied to a prior financial shortfall. The piece suggests investors should monitor whether Axon’s consistency continues to widen its revenue gap versus Celsius and how Celsius responds to recent internal adjustments in upcoming earnings.

Analysis

AXON is the better quality compounder, but the market is paying for near-flawless execution and will punish any hint that software mix or margin leverage stalls. At ~250x earnings, the stock is less a public-safety operator and more a long-duration cash-flow bond: the main risk is multiple compression if growth stays high but operating margin remains stuck in the mid-single digits. The competitive edge is real, though; agencies tend to standardize once embedded, which creates a multi-year replacement barrier that should keep peers like MSI from easily dislodging the installed base.

CELH looks like a channel/brand execution story rather than a pure demand-growth story. The important second-order issue is shelf-space economics: if velocity does not reaccelerate, retailers will rationalize assortment toward stronger turns, which benefits MNST and private labels more than CELH; PEP’s distribution muscle helps, but it can also become a leverage point if the brand weakens inside the portfolio. The legal/leadership overhang makes this a months-not-days catalyst path, with scanner data and channel inventory the key tell.

Contrarian view: the consensus is treating this as a simple quality-vs-cyclicality comparison, but the real tradeable variable is operating leverage. AXON can look “safe” until the market realizes revenue consistency is already priced in and margin expansion is the missing proof point; CELH can look “broken” while actually setting up a cleaner base if new leadership stabilizes execution and organic growth normalizes. The next 1-3 quarters matter most; over 6-18 months, AXON’s recurring software mix is still structurally superior, but CELH has more upside if the reset is deeper than the market expects.

Key Decisions for Investors

• Long AXON on pullbacks, not strength; hold for 3-6 months and use a hard risk check if revenue growth slips below 25% or operating margin fails to improve toward 7%+.
• Pair trade: long MNST / short CELH over the next 1-3 quarters to express relative shelf-space and scanner-data risk; cover the short if CELH shows two consecutive quarters of reaccelerating organic revenue and stable channel inventory.
• Avoid paying up for AXON at current multiples unless the next earnings print shows meaningful operating leverage; otherwise treat it as a hold and let the valuation reset do the work.
• Watch PEP as a low-beta beneficiary of distribution optionality, but keep position sizing modest; the upside is incremental, not transformational, unless CELH regains clear brand momentum.
• If you want a catalyst trigger, set an alert on CELH for any management guidance raise or evidence of retail de-stocking; that would be the signal to cover shorts quickly because the setup is more execution-sensitive than valuation-sensitive.